
Obesity rates have spiked over the past few decades, displaying itself a significant crisis.

Conversations around menopause symptoms are becoming more common, but there is such a thing as potentially calling too much attention, especially in the workplace, according to Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health.

Gaps in funding caused by the potential $5 billion budget cut to the National Institutes of Health would be “almost impossible” to fill, according to Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D.

In this role, Virtell will oversee the strategy, daily operations and expansion of Cigna Healthcare’s Supplemental Health division, which helps customers manage out-of-pocket expenses from serious illnesses or accidents.

Bias and stigma are to blame for the way women’s health research has fallen behind, according to Monica Christmas, M.D., director of UChicago Medicine’s menopause program and the Center for Women's Integrated Health and Valentina Sartori, Ph.D., the leader of the McKinsey Health Institute's Life Sciences Practice in Europe.

Funding will be cut to $10 million, which is a nearly 90% decrease from 2024’s budget of $98 million.

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.

Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, spoke with Managed Healthcare Executive, about the possible impacts of the NIH’s cuts to indirect research funding.
